INTRODUCTION
============

*FLT3* mutations are common cytogenetic changes in acute myeloid leukemia (AML). Internal tandem duplication (ITD) of exon 14 or 15 is detected in 20-30% of patients ([@B1]-[@B3]) and a mutation of D835 in exon 20 in 7% of patients ([@B4]-[@B7]). Many clinical studies have shown that patients with an ITD at diagnosis have frequent disease relapse and a short duration of survival when compared to patients without an ITD ([@B8]-[@B17]). Two prior Korean trials included 165 adult ([@B14]) and 61 pediatric ([@B16]) patients with AML, and showed similar results; patients with an ITD at diagnosis had reduced event-free survival and similar overall survival when compared to patients without an ITD. The incidence of ITD in the 2 Korean studies was 35.2% and 6.6%, respectively ([@B14], [@B16]). A second mutation of *FLT3* involves the tyrosine kinase domain (TKD) at D835. Its incidence is relatively low and its prognostic value has not been determined ([@B8], [@B14], [@B18]). However, one of several studies on TKD showed that the survival of patients with TKD at diagnosis was longer than those without TKD ([@B18]).

Several studies have investigated the variability of the *FLT3* mutation in patients with AML during treatment ([@B13], [@B17], [@B19]-[@B22]). When compared to diagnosis, leukemic relapse occurred with persistent, newly developed or disappeared ITD. Because of the small number of patients in prior studies, the understanding of the *FLT3* changes is incomplete. In addition, the role of the *FLT3* status in disease remission or persistence during therapy has not been evaluated. Therefore, we studied *FLT3* mutations (ITD and TKD) at diagnosis and evaluated their variability during disease remission relapse or persistence with therapy in Korean patients with AML.

MATERIALS AND METHODS
=====================

Eligibility
-----------

From March 1996 to August 2005, 226 patients from three centers were diagnosed with AML and underwent induction chemotherapy according to the center\'s protocol usually including anthracycline and cytarabine. Among them, 33 patients did not receive chemotherapy. Twenty-four patients did not receive chemotherapy due to co-morbid conditions or advanced age, and pretreatment mortality occurred in nine patients. All patients\' bone marrow (BM) samples at diagnosis were available, but samples after induction were available for 111 patients. BM samples were classified into four groups: Group A samples at diagnosis, Group B first relapse or more, Group C first remission or more, and Group D first induction failure or more. The number of patient samples available at diagnosis and relapse was 54 for A/B, 91 for A/C and 28 for A/D. All patients provided informed consent and the individual institutional review boards at each center approved the study protocol.

Detection of *FLT3* ITD and TKD
-------------------------------

Mononuclear cells from the BM aspirate were isolated using Histopaque-1077 (Sigma, St. Louis, MO, U.S.A.) and then DNA was extracted using the QIAmp DNA Blood Mini Kit (Qiagen, Hilden, Germany). Polymerase chain reaction (PCR) for the ITD was carried out as described previously ([@B1]). We used a 100 ng sample of each patient\'s DNA, which was amplified in a 36-cycle PCR reaction at an annealing temperature of 56℃. We used 10 µM/L of two reverse primers (11R of 5\'-ACTCTA AATTTTCTCT-3\', and 12R of 5\'-CTTTCAGCATTTTGACGGCAACC-3\') for each reaction and 10 µM/ L of a common forward primer (3\'-GCAATTTAGGTATGAAAGCCAGC-5\'). The PCR for TKD was performed as described previously ([@B3]). We amplified exon 17 of the *FLT3* gene by the genomic PCR method using the primers (17F of 5\'-CCGCCAGGAACGTGCTTG-3\', and 17R of 5\'-GCAG-CCTCACATTGCCCC-3\'). Amplified products were digested with *Eco* RV; then they were subjected to electrophoresis on an agarose gel.

Statistical analysis
--------------------

The correlation of the clinical characteristics and the *FLT3* ITD or TKD mutations at diagnosis was analyzed in 226 patients with AML, including or excluding those with M3 disease. Differences in the median variables of age, peripheral white blood cell (WBC) counts, platelet counts and the serum lactate dehydrogenase (LDH) concentration were analyzed by the Mann-Whitney U test. The analysis of data frequencies was performed using the Fisher\'s exact test for 2 × 2 tables or the chi-square test for larger tables. Survival probabilities were estimated by the Kaplan-Meyer method, and differences in the survival distributions were evaluated by the log-rank test. These statistical analyses were performed with SPSS software, version 13.0 (Chicago, IL, U.S.A.). For all analyses, the *p* values were 2-tailed, and a *p* value of less than 0.05 was considered statistically significant.

RESULTS
=======

Clinical characteristics of AML patients with or without *FLT3* mutations
-------------------------------------------------------------------------

Among the 226 AML patients, 29 (12.8%) had an ITD, 6 (2.7%) had a TKD and 191 (84.5%) had neither (wild type). No patient had an ITD and TKD concomitantly. When compared to patients with the wild type, the patients with an ITD or a TKD were significantly older (*p*=0.020) and had higher WBC (*p*=0.008) counts. Their subtypes were most frequently from M0 to M5. The presence of *FLT3* mutations was not related to gender, previous hematological disease, cytogenetic changes, or high serum LDH ([Table 1](#T1){ref-type="table"}).

The effect of *FLT3* mutations on remission and survival
--------------------------------------------------------

Among the 193 patients receiving induction chemotherapy, 182 patients were available to evaluate for remission and 151 patients achieved complete remission; the remission rate (RR) was 78%. Nine patients died of therapy-related complications within 30 days. Among 22 patients with an ITD at diagnosis, 19 patients achieved remission. There was no significant difference in the RR between patients with an ITD and the wild type (*p*=0.651). Therefore, the presence of a *FLT3* mutation did not influence the RR (*p*=0.824).

At a median follow-up of 61 (11-123) months, 90 of the 236 patients (39.8%) were still alive. The median overall survival (OS) was 14 (95% CI, 12-17), 14 (4-23) and 14 (10-18) months in all patients, those with an ITD and those with the wild type, respectively (*p*=0.530). The median event-free survival (EFS) was 10 (8-12), 7 (2-11) and 11 (7-14) months for all patients, those with an ITD and those with the wild type, respectively (*p*=0.094). When excluding the M3 types (N=20), comparison of the OS between the ITD and wild type patients showed no difference; however, the EFS with an ITD was significantly shortened (*p*=0.0079, [Fig. 1](#F1){ref-type="fig"}). In the multivariate analysis in treated non-M3 patients (N=176), the significant factors influencing the OS and the EFS were cytogenetic risk group ([@B23]), the presence of a complete remission after the first induction and post-remission transplantation either autologous or allogeneic ([Table 2](#T2){ref-type="table"}). However, neither a *FLT3* mutation nor an ITD affected survival in this analysis.

Variability of the *FLT3* mutation
----------------------------------

The changes of the *FLT3* ITD are summarized in [Fig. 2](#F2){ref-type="fig"}. At hematological remission, all samples were negative for an ITD even if there was an initially positive ITD (N=14). The ITD reappeared with relapse in 6 out of 9 patients, and was de novo in one of 45 patients. Induction failures with a persistent ITD were common. One patient had a lately occurred ITD at the second induction failure. The TKD changes were evaluated in patients from one center. Among 23 samples at relapse, two had a TKD. One patient had a TKD initially, and it reappeared on relapse. The other patient had an ITD only at diagnosis, and showed a newly appeared TKD at remission, which persisted at relapse and during the refractory period despite negative conversion of ITD.

DISCUSSION
==========

Our study showed a low frequency of *FLT3* ITD and TKD, 12.8% and 2.7%, respectively, in Korean AML patients. This frequency was about two-thirds lower than reports from other Asian and Western patients. ([@B1], [@B2], [@B4], [@B8]-[@B13], [@B19], [@B24]). A recent Korean study on M3 disease showed a relatively low frequency of ITD and TKD, 12.0% and 9.3% ([@B25]). Another unpublished Korean report also showed a low frequency of the *FLT3* mutation in AML patients, the ITD was 10.4% and the TKD was 9.1% ([@B26]). To determine the association with age, we separated the patients into 148 adults and 72 pediatric patients. The adult group had the *FLT3* mutation in 16% of cases and the pediatric group in 6%. Previous reports showed the *FLT3* mutation in 20-30% of adults and in 9-11.5% of pediatric aged patients ([@B27], [@B28]). Therefore, the information to date shows that the frequency of the *FLT3* mutation, especially the ITD, is low in Korean AML patients in both the adult and pediatric age groups.

The prognostic value of the *FLT3* mutation in AML was evaluated in a group of patients with normal karyotypes excluding those with known prognostic cytogenetic changes. About half of the AML patients had a normal karyotype or an intermediate cytogenetic risk ([@B24], [@B29]). The *FLT3* ITD at diagnosis in these patients was associated with a significantly shortened EFS and OS ([@B8]-[@B17]). Therefore, intensified consolidation including transplantation or clinical trials targeting the *FLT3* mutation should be considered in patients with an ITD ([@B30], [@B31]). The variability of the *FLT3* ITD, during treatment in this study, supports a pattern of reappearance of the ITD with disease relapse and persistent ITD in refractory disease, which suggests chemo-resistance of the ITD-positive leukemic clones.

Our study included only 20 patients with M3. Recently several studies reported that M3 patients with ITD had a poor survival ([@B25], [@B32]). Clinical trials with *FLT3*-targeting agents to ATRA and anthracycline-based treatment may provide more information on the role of *FLT3* in M3.

Although a more sensitive method for detection of ITD, such as the genescan technique, ([@B21]) was not used in our trial, all samples at remission were negative for ITD. In a follow-up to our study (data not included) genescan detected ITD in three out of 101 samples at remission. Therefore, future studies should use the more sensitive methods now available instead of the PCR.

In summary, this study included the largest number of Korean patients with AML to date, and showed a relatively low frequency of *FLT3* ITD consistent with prior reports. ITD in Korean non-M3 AML patients was associated with poor EFS. In addition, the variability of ITD, during treatment follow-up, suggested chemo-resistance of the ITD-positive leukemic clones. Therefore, aggressive therapeutic approaches should be considered in AML patients with ITD at diagnosis.
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###### 

Patient and disease characteristics according to *FLT3* mutational status
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^\*^, *FLT3* internal tandem duplication (ITD) or D835 point mutation of tyrosine kinase domain (TKD) was identified in this group; ^†^, mixed means biphenotypic or bilineage leukemia.

RAEB-t, refractory anemia with excess blast in transformation; CBC, complete blood count; LDH, latacte dehydrogenase.

###### 

Multivariate analysis of the significant factors for event-free (EFS) and overall survival (OS) in treated non-M3 patients (N=176)
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HR, hazard ratio; Cyto, cytogenetic 3 risk groups consisted of favorable, intermediate, and adverse risk groups; 1st CR, complete hematologic remission to the first induction treatment; SCT, stem cell transplantation.
